Related Experiment Videos
Phase II trial of methylglyoxal-bis-guanylhydrazone (methyl-GAG) in patients with soft-tissue sarcomas
American Journal of Clinical Oncology
|August 1, 1985
Abstract:
A phase II study of Methylglyoxal-bis-guanylhydrazone (Methyl-GAG) was conducted on 20 previously treated patients with soft-tissue sarcomas. No major responses were seen among 18 adequately treated patients. Toxicity including severe fatigue, muscle pains, and pharyngitis was noted in most patients. Methyl-GAG does not have significant antitumor activity in previously treated patients with soft-tissue sarcomas.
Insights
Methylglyoxal-bis-guanylhydrazone (Methyl-GAG) showed no significant antitumor activity in patients with soft-tissue sarcomas. The drug caused severe fatigue, muscle pains, and pharyngitis in most participants.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Soft-tissue sarcomas are rare cancers requiring effective treatment options.
- Methylglyoxal-bis-guanylhydrazone (Methyl-GAG) is an investigational agent explored for its potential anticancer effects.
Purpose of the Study:
- To evaluate the efficacy and safety of Methylglyoxal-bis-guanylhydrazone (Methyl-GAG) in patients with previously treated soft-tissue sarcomas.
Main Methods:
- A Phase II clinical trial was conducted.
- Twenty patients with soft-tissue sarcomas who had received prior treatment were enrolled.
- Eighteen patients received adequate treatment and were assessed for response and toxicity.
Main Results:
- No major anti-tumor responses were observed in the 18 adequately treated patients.
- The most frequent toxicities included severe fatigue, myalgia, and pharyngitis.
- These adverse events were noted in the majority of the participating patients.
Conclusions:
- Methylglyoxal-bis-guanylhydrazone (Methyl-GAG) demonstrated limited clinical benefit in this patient population.
- The observed toxicity profile suggests potential safety concerns for Methyl-GAG in soft-tissue sarcoma treatment.